Dashboard
Manage Tickers

XERS Xeris Biopharma Holdings, Inc.

Nasdaq xerispharma.com


$ 7.27 $ -0.33 (-4.35 %)    

Thursday, 13-Nov-2025 15:59:57 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 608.59 $ -9.26 (-1.5 %)
DIA $ 475.50 $ -6.59 (-1.37 %)
SPY $ 672.57 $ -8.41 (-1.24 %)
TLT $ 89.38 $ -0.42 (-0.46 %)
GLD $ 384.40 $ -4.31 (-1.11 %)
$ 7.26
$ 7.60
$ 7.25 x 277
$ 7.32 x 50
$ 7.26 - $ 7.75
$ 2.82 - $ 10.08
2,737,750
na
1.2B
$ 1.31
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 03-06-2025 01-01-1970 10-K
5 11-08-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 03-06-2024 12-31-2023 10-K
9 11-09-2023 09-30-2023 10-Q
10 08-08-2023 06-30-2023 10-Q
11 05-09-2023 03-31-2023 10-Q
12 03-08-2023 12-31-2022 10-K
13 11-09-2022 09-30-2022 10-Q
14 08-10-2022 06-30-2022 10-Q
15 05-11-2022 03-31-2022 10-Q
16 03-11-2022 12-31-2021 10-K
17 11-10-2021 09-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

xeris-biopharma-holdings-raises-fy2025-sales-guidance-from-280000m-290000m-to-285000m-290000m-vs-286467m-est
Xeris Biopharma Holdings Raises FY2025 Sal...
11/06/2025 12:03:16

Xeris Biopharma Holdings (NASDAQ:XERS) raises FY2025 sales outlook from $280.000 million-$290.000 million to $285.000 million-$...

xeris-biopharma-holdings-q3-sales-74380m-beat-74180m-estimate
Xeris Biopharma Holdings Q3 Sales $74.380M...
11/06/2025 12:02:50

Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly sales of $74.380 million which beat the analyst consensus estimate of...

earnings-scheduled-for-november-6-2025
Earnings Scheduled For November 6, 2025
11/06/2025 11:12:19

american-regent-and-xeris-pharmaceuticals-launch-gvoke-vialdx-first-concentrated-liquid-glucagon-for-diagnostic-gi-procedures
American Regent And Xeris Pharmaceuticals ...
08/27/2025 12:39:20

First concentrated, ready-to-dilute liquid glucagon available for diagnostic proceduresSHIRLEY, N.Y., Aug. 27, 2025 /PRNewswire...

xeris-announces-us-patent-listing-in-orange-book-extending-recorlev-protection-to-2040-for-endogenous-cushings-syndrome-treatment
Xeris Announces US Patent Listing In Orang...
08/25/2025 11:12:08

hc-wainwright--co-assumes-xeris-biopharma-holdings-at-buy-announces-price-target-of-10
HC Wainwright & Co. Assumes Xeris Biopharm...
08/12/2025 11:30:57

HC Wainwright & Co. analyst Brandon Folkes assumes Xeris Biopharma Holdings (NASDAQ:XERS) with a Buy rating and announce...

xeris-biopharma-holdings-raises-fy2025-sales-guidance-from-260000m-275000m-to-280000m-290000m-vs-269380m-est
Xeris Biopharma Holdings Raises FY2025 Sal...
08/07/2025 11:05:31

xeris-biopharma-holdings-q2-eps-001-beats-002-estimate-sales-71539m-beat-64575m-estimate
Xeris Biopharma Holdings Q2 EPS $(0.01) Be...
08/07/2025 11:04:45

Core News & Articles
Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

oppenheimer-maintains-outperform-on-xeris-biopharma-holdings-raises-price-target-to-7
Oppenheimer Maintains Outperform on Xeris ...
05/09/2025 17:51:53

Oppenheimer analyst Leland Gershell maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Outperform and raises the price ...

xeris-biopharma-holdings-raises-fy2025-sales-guidance-from-25500m-27500m-to-26000m-27500m-vs-31763m-est
Xeris Biopharma Holdings Raises FY2025 Sal...
05/08/2025 11:07:05

xeris-biopharma-holdings-q1-eps-006-misses-004-estimate-sales-6012m-miss-6265m-estimate
Xeris Biopharma Holdings Q1 EPS $(0.06) Mi...
05/08/2025 11:01:33

Core News & Articles
Earnings Scheduled For May 8, 2025
05/08/2025 08:33:13

earnings-outlook-for-xeris-biopharma-holdings
Earnings Outlook For Xeris Biopharma Holdings
05/07/2025 15:02:14

xeris-announces-fda-approval-of-supplemental-new-drug-application-of-gvoke-vialdx-for-use-as-a-diagnostic-aid-xeris-also-announced-it-has-partnered-with-american-regent-to-commercialize-gvoke-vialdx-financial-terms-were-not-disclosed
Xeris Announces FDA Approval Of Supplement...
03/17/2025 12:10:39

First concentrated, ready-to-dilute liquid glucagon available for growing procedural gastroenterology marketAmerican Regent to ...

piper-sandler-reiterates-neutral-on-xeris-biopharma-holdings-raises-price-target-to-4
Piper Sandler Reiterates Neutral on Xeris ...
03/07/2025 15:42:48

Piper Sandler analyst David Amsellem reiterates Xeris Biopharma Holdings (NASDAQ:XERS) with a Neutral and raises the price t...

hc-wainwright--co-reiterates-buy-on-xeris-biopharma-holdings-raises-price-target-to-8
HC Wainwright & Co. Reiterates Buy on Xeri...
03/07/2025 11:50:49

HC Wainwright & Co. analyst Oren Livnat reiterates Xeris Biopharma Holdings (NASDAQ:XERS) with a Buy and raises the pric...

xeris-biopharma-expects-2025-revenue-of-255m-275m-representing-growth-of-over-30-at-the-mid-point-of-the-range-versus-consensus-of-23984m
Xeris Biopharma Expects 2025 Revenue Of $2...
03/06/2025 12:05:52

xeris-biopharma-holdings-q4-2024-gaap-eps-003-beats-006-estimate-sales-6010m-beat-5810m-estimate
Xeris Biopharma Holdings Q4 2024 GAAP EPS ...
03/06/2025 12:01:51

Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate...

earnings-scheduled-for-march-6-2025
Earnings Scheduled For March 6, 2025
03/06/2025 08:32:20

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION